Creative Biolabs is the leading custom service provider with extensive experience in various antibody production and engineering fields.
Many different strategies are being investigated to develop ""off-the-shelf"" CAR T-cell therapies. The cumbersome manufacturing process and high cost of autologous CAR T cells may prevent some patients from receiving the treatment. Using induced pluripotent stem cells (iPSCs) as a starting source for CAR T cells is an attractive approach.
Our CAR-iT cells are engineered by incorporating a second-generation CAR into iPSCs-derived T cells using lentiviral transduction technology. These CAR-iT cells are expected to lysis tumor cells in vitro and demonstrated anti-tumor function in vivo.
Creative Biolabs is the leading custom service provider with extensive experience in various antibody production and engineering fields.